Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Hong Kong ETF (EWH) vs Twist Bioscience Corp (TWST) Price & Performance

iShares MSCI Hong Kong ETFTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Hong Kong ETF vs Twist Bioscience Corp — how do they compare? iShares MSCI Hong Kong ETF trades at $21.93 (market cap $1.16B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 8.7× iShares MSCI Hong Kong ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Twist Bioscience Corp for 27 Days on average.

EWHTWST
Market Cap
$1.16B$10.08B
Volume
3,176,5234,229,037
Sector
Broad Market / FactorHealth
52-Week High
$24.55$205.00
52-Week Low
$20.66$25.45
Typical Hold Time
61 Days27 Days
Enterprise Value
—$10.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Hong Kong ETF

EWH, the iShares MSCI Hong Kong ETF, trades at $21.58, down 0.19% today amid bearish technical signals with moving averages indicating strong selling pressure. The ETF tracks Hong Kong equities, which have faced volatility due to Federal Reserve policy and US-Iran tensions, as reflected in recent Hang Seng Index declines. Key support sits at $21 with resistance clustered around $22. Financial ratios are unavailable in the current dataset.

Outlook remains cautious given bearish technicals and macroeconomic headwinds impacting Hong Kong markets. Opportunities exist if geopolitical tensions ease and technology stocks rebound, but risks include prolonged Fed tightening and China economic struggles. Investors should monitor Hang Seng Index momentum and institutional flow trends for directional cues.

Twist Bioscience Corp

TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.

The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWH
100% Buy0% Sell
Avg holding period · 61 Days
TWST
37% Buy63% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About iShares MSCI Hong Kong ETF

EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.

Read more on EWH →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →